Cobenfy is the first new drug to get Food and Drug Administration approval to treat schizophrenia with more manageable side effects than the leading treatment. (Photo courtesy of Bristol Myers Squibb)
Screen Shot 2025-01-02 at 3.05.01 PM
Cobenfy is the first new drug to get Food and Drug Administration approval to treat schizophrenia with more manageable side effects than the leading treatment. (Photo courtesy of Bristol Myers Squibb)